The European Medicines Agency (EMA) has recommended against Adempas (riociguat) for patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP), according to a recent press release. EMA’s recommendation follows Bayer Pharmaceuticals‘ announcement in May for ... Read more